SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Misaki Ono, Takako Higuchi, Mikako Takeshima, Chen Chen, Shuji Nakano, Differential anti-tumor activities of curcumin against Ras- and Src-activated human adenocarcinoma cells, Biochemical and Biophysical Research Communications, 2013,

    CrossRef

  2. You have free access to this content2
    Takamitsu Sasaki, Hiroki Kuniyasu, Yi Luo, Daisuke Kato, Satoshi Shinya, Kiyomu Fujii, Hitoshi Ohmori, Yuichi Yamashita, Significance of epithelial growth factor in the epithelial–mesenchymal transition of human gallbladder cancer cells, Cancer Science, 2012, 103, 6
  3. 3
    Hyun-Jin Nam, Hwang-Phill Kim, Young-Kwang Yoon, Sang-Hyun Song, Ah-Rum Min, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang, The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines, Investigational New Drugs, 2012, 30, 6, 2148

    CrossRef

  4. 4
    Cheng-Yi Chang, Chiung-Chyi Shen, Hong-Lin Su, Chun-Jung Chen, Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation, Journal of Neuro-Oncology, 2011, 105, 3, 507

    CrossRef

  5. 5
    Yi-Fan Zhao, Chong-Ren Wang, Yan-Ming Wu, Sheng-Lin Ma, Yuan Ji, Yan-Jun Lu, P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment, Biomedicine & Pharmacotherapy, 2011, 65, 3, 151

    CrossRef

  6. You have free access to this content6
    Moon-Taek Park, Min-Jeong Song, Eun-Taex Oh, Hyemi Lee, Bo-Hwa Choi, Seong-Yun Jeong, Eun-Kyung Choi, Heon Joo Park, The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase, British Journal of Pharmacology, 2011, 163, 3
  7. 7
    Xishan Xiong, Yingwei Zhang, Xiang Gao, Zheyi Dong, Lin Li, Chengcheng Ji, Lili Fu, Xiaomin Luo, Hong Liu, Changlin Mei, B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest, Investigational New Drugs, 2010, 28, 1, 26

    CrossRef

  8. 8
    Kenji Takeuchi, Fumiaki Ito, EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors, FEBS Journal, 2010, 277, 2
  9. 9
    Xishan Xiong, Lili Fu, Li Wang, Houan Cai, Lin Li, Hualiang Jiang, Wenhu Duan, Changlin Mei, Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo, Investigational New Drugs, 2009, 27, 1, 1

    CrossRef

  10. 10
    Beata Zahorowska, Philip J. Crowe, Jia-Lin Yang, Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs, Journal of Cancer Research and Clinical Oncology, 2009, 135, 9, 1137

    CrossRef

  11. 11
    Kenji Takeuchi, Tomohiro Shin-ya, Kazuto Nishio, Fumiaki Ito, Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase, FEBS Journal, 2009, 276, 5
  12. 12
    Dongxu FU, Linjie TIAN, Zhi PENG, Weiwei DENG, Jinsong YUAN, Dalong MA, Taiping SHI, Dianjun LI, Ying WANG, Overexpression of CHMP6 Induces Cellular Oncosis and Apoptosis in HeLa Cells, Bioscience, Biotechnology, and Biochemistry, 2009, 73, 3, 494

    CrossRef

  13. 13
    Giuseppe Tonini, Vladimir Virzì, Maria Elisabetta Fratto, Bruno Vincenzi, Daniele Santini, Targeted therapy in biliary tract cancer: 2009 update, Future Oncology, 2009, 5, 10, 1675

    CrossRef

  14. 14
    Gee-Chen Chang, Chang-Tze Ricky Yu, Ching-Hwa Tsai, Jia-Rong Tsai, Jen-Chi Chen, Chun-Chi Wu, Wen-Jun Wu, Shih-Lan Hsu, An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells, European Journal of Pharmacology, 2008, 600, 1-3, 37

    CrossRef

  15. 15
    Melanie B Thomas, Targeted therapies for cancer of the gallbladder, Current Opinion in Gastroenterology, 2008, 24, 3, 372

    CrossRef

  16. 16
    Melanie B. Thomas, Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy, Critical Reviews in Oncology/Hematology, 2007, 61, 1, 44

    CrossRef

  17. 17
    Lina Albitar, Mark B. Carter, Suzy Davies, Kimberly K. Leslie, Consequences of the loss of p53, RB1, and PTEN: Relationship to gefitinib resistance in endometrial cancer, Gynecologic Oncology, 2007, 106, 1, 94

    CrossRef

  18. 18
    Aurélie Telliez, Matthieu Desroses, Nicole Pommery, Olivier Briand, Amaury Farce, Guillaume Laconde, Amélie Lemoine, Patrick Depreux, Jean-Pierre Hénichart, Derivatives of Iressa, a Specific Epidermal Growth Factor Receptor Inhibitor, are Powerful Apoptosis Inducers in PC3 Prostatic Cancer Cells, ChemMedChem, 2007, 2, 3
  19. 19
    Florian Eckel, Roland M Schmid, Emerging drugs for biliary cancer, Expert Opinion on Emerging Drugs, 2007, 12, 4, 571

    CrossRef

  20. 20
    Emily K.Y. Lam, L. Yu, Helen P.S. Wong, William K.K. Wu, Vivian Y. Shin, Emily K.K. Tai, Wallace H.L. So, Patrick C.Y. Woo, C.H. Cho, Probiotic Lactobacillus rhamnosus GG enhances gastric ulcer healing in rats, European Journal of Pharmacology, 2007, 565, 1-3, 171

    CrossRef